EPICS Therapeutics
Oncology Therapeutics · Exhibitions
Patents: 5No open roles listed
Data updated Nov 20, 2026Full reportReport a mistake
Lately:1 news story in 90 daysFollow changes →
Facts
as of Nov 20, 2026EPICS Therapeutics pioneers best-in-class small-molecule modulators of RNA epigenetics, with lead program EP102, a METTL3 inhibitor now advancing in patients with solid tumors.
- Legal name
- EPICS Therapeutics SA
- Register numbers
- VAT BE0690759071 · KBO 0690759071
- Official records
- LEI 875500LY5TWB3RTQQO43
- Website
- epicstherapeutics.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Products
Products →EPICS Therapeutics has 1 clinical trials on record, 1 under way.
Clinical trials
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
phase 1 · under way · 48 participants · Advanced Solid Tumor (Phase 1)
Jul 2025
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →EPICS Therapeutics in public registers.
Legal entity active
EPICS Therapeutics SA
Not checked
No match
None
None
Patents
5
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
